Literature DB >> 28870085

A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache.

Sarah Cargnin1, Michele Viana2, Grazia Sances2, Cristina Tassorelli2,3, Salvatore Terrazzino1.   

Abstract

Purpose of review Medication-overuse headache is a secondary chronic headache disorder, evolving from an episodic primary headache type, caused by the frequent and excessive use of headache symptomatic drugs. While gene polymorphisms have been deeply investigated as susceptibility factors for migraine, little attention has been paid to medication-overuse headache genetics. In the present study we conducted a systematic review to identify, appraise and summarize the current findings of gene polymorphism association studies in medication-overuse headache. Methods A comprehensive literature search was conducted on PubMed and Web of Knowledge databases of primary studies that met the diagnostic criteria for medication-overuse headache according to the temporally-relevant Classification of Headache Disorder of the International Headache Society. Results A total of 17 candidate gene association studies focusing on medication-overuse headache were finally included in the qualitative review. Among these, 12 studies investigated the role of common gene polymorphisms as risk factors for medication-overuse headache susceptibility, six studies focused on the relationship with clinical features of medication-overuse headache patients, and four studies evaluated their role as determinants of clinical outcomes in medication-overuse headache patients. Conclusion Results of single studies show a potential role of polymorphic variants of the dopaminergic gene system or of other genes related to drug-dependence pathways as susceptibility factors for disease or as determinants of monthly drug consumption, respectively. In this systematic review, we summarize the findings of gene polymorphism association studies in medication-overuse headache and discuss the methodological issues that need to be addressed in the design of future studies.

Entities:  

Keywords:  Medication-overuse headache; genetics; polymorphism; systematic review

Mesh:

Year:  2017        PMID: 28870085     DOI: 10.1177/0333102417728244

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Medication-overuse headache: painkillers are not always the answer.

Authors:  Benjamin R Wakerley
Journal:  Br J Gen Pract       Date:  2020-01-30       Impact factor: 5.386

2.  Personality and Personality Disorders in Medication-Overuse Headache: A Controlled Study by SWAP-200.

Authors:  Federica Galli; Annalisa Tanzilli; Alessandra Simonelli; Cristina Tassorelli; Grazia Sances; Micol Parolin; Patrizia Cristofalo; Ivan Gualco; Vittorio Lingiardi
Journal:  Pain Res Manag       Date:  2019-06-12       Impact factor: 3.037

3.  Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.

Authors:  Jill C Rau; Edita Navratilova; Janice Oyarzo; Kirk W Johnson; Sheena K Aurora; Todd J Schwedt; David W Dodick; Frank Porreca
Journal:  Cephalalgia       Date:  2020-06-24       Impact factor: 6.292

4.  Using a Chatbot to Study Medication Overuse Among Patients Suffering From Headaches.

Authors:  Arthur Bézie; Valentin Morisseau; Romain Rolland; Arthur Guillemassé; Benoît Brouard; Benjamin Chaix
Journal:  Front Digit Health       Date:  2022-03-17

5.  Differential medication overuse risk of novel anti-migraine therapeutics.

Authors:  Chonlawan Saengjaroentham; Lauren C Strother; Isaac Dripps; Mohammad Rayhan Sultan Jabir; Amynah Pradhan; Peter J Goadsby; Philip R Holland
Journal:  Brain       Date:  2020-09-01       Impact factor: 13.501

Review 6.  Medication-overuse headache: a widely recognized entity amidst ongoing debate.

Authors:  Nicolas Vandenbussche; Domenico Laterza; Marco Lisicki; Joseph Lloyd; Chiara Lupi; Hannes Tischler; Kati Toom; Fenne Vandervorst; Simone Quintana; Koen Paemeleire; Zaza Katsarava
Journal:  J Headache Pain       Date:  2018-07-13       Impact factor: 7.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.